Altogether, the investigation of p53 functionality in BRCA1 and PALB2 mutant cancers may raise novel prospects for combination therapies against breast cancers with homologous recombination deficiency by targeting p53-dysregulated cells and BRCA1-deficiency using target therapies. Here, TP53 is linked to breast carcinoma.